Compound comparisons
Side-by-side comparisons of related research compounds: how they differ in structure, in the receptors or pathways they act on, and in the evidence published so far. Each comparison opens with a short answer, sets out the differences in a table, and lists every study it cites with a link to PubMed or the DOI. The specification table at the end of each comparison (sizes, prices, form, molecular weight, CAS number and whether a certificate is published) is rendered from the same records as the product pages, so it always matches them.
-
Comparison
BPC-157 vs TB-500: how they differ
BPC-157 is a defined 15-residue synthetic peptide. TB-500 is a supplier name: the biology is published for full-length thymosin beta-4, while one analysed TB-500 product was a seven-residue fragment.
-
Comparison
Retatrutide vs tirzepatide: how they differ
Tirzepatide acts at two receptors, GIP and GLP-1; retatrutide adds a third, glucagon. Tirzepatide is an approved medicine in the United States, while retatrutide was still investigational when this was written.